In this prospective, multicenter, double-blind study, the efficacy of ciprofloxacin was compared with that of clarithromycin as therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) from whom a pretherapy pathogen was isolated; the efficacy was measured by the infection-free interval. Clinical and microbiological responses at the end of therapy were secondary efficacy variables. Patients randomly received either ciprofloxacin or clarithromycin (500 mg twice a day for 14 days). Three hundred seventy-six patients with acute exacerbations of chronic bronchitis were enrolled in the study of whom 234 had an ABECB. Clinical resolution was observed in 90% (89 of 99) of ciprofloxacin recipients and 82% (75 of 91) of clarithromycin recipients for whom efficacy could be evaluated. The median infection-free interval was 142 days for ciprofloxacin recipients and 51 days for clarithromycin recipients (P Å .15). Bacteriologic eradication rates were 91% (86 of 95) for ciprofloxacin recipients and 77% (67 of 87) for clarithromycin recipients (P Å .01). In summary, compared with clarithromycin, treatment of ABECB with ciprofloxacin was associated with a trend toward a longer infection-free interval and a statistically significantly higher bacteriologic eradication rate.
Up to one in five adults residing in the United States are influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae afflicted with chronic bronchitis [1] . Although systemic evidence [2, 3] . In addition, there has been an increase of infections due that a patient's chronic bronchitis has worsened due to an infecto Haemophilus parainfluenzae, Klebsiella pneumoniae, and tious etiology is often lacking, acute bacterial exacerbations of Pseudomonas aeruginosa [3] . chronic bronchitis (ABECB) are usually manifested by increased A major explanation for the controversy surrounding use of cough, increased daily sputum production, and increased sputum antimicrobial treatment for patients with AECB is because only purulence, similar to the clinical presentation of all acute exacer-50% to 60% of episodes are proven to be due to bacterial bations of chronic bronchitis (AECB) [2] . The bacterial pathogens infection (i.e., ABECB). The significant amount of morbidity most commonly associated with ABECB include Haemophilus experienced by these chronically ill patients suggests that empirical antimicrobial therapy is warranted even when the etiology has not been ascertained [4 -6] . Although episodes of AECB resolve in some patients without antimicrobial therapy, Received 15 October 1997; revised 7 May 1998. their illness is often prolonged and -in those with ABECB - antimicrobial therapy is made, then the increasing problems of
Informed consent was obtained from the patients, their parents, or their bacterial resistance, including penicillin-resistant pneumococci guardians, and the guidelines for human experimentation of the U.S. Departand b-lactamase-producing M. catarrhalis and H. influenzae ment of Health and Human Services were followed in the conduct of this study. [7] , should be considered. nonspecific criteria for study entry, absence of gram staining, AECB, Saint et al. [8] recently reported a meta-analysis of the following signs: fever (temperature, ú100.4ЊF or ú38ЊC) without other cause, increased wheezing, increased cough, nine studies conducted between 1955 and 1994; they found that antimicrobials provided some clinical benefit compared and/or increased respiratory rate as compared with their stable baseline condition. All patients had to have an acute bacterial with no therapy at all. Other ''well-designed'' studies showed that the incidence of failure of treatment with older antimicrobiinfection as documented by gram staining of sputum that revealed õ10 squamous oropharyngeal epithelial cells, §25 leuals (e.g., ampicillin, amoxicillin, doxycycline, and trimethoprim-sulfamethoxazole) is comparatively low, but the infeckocytes per low-power field, and a likely bacterial pathogen in increased numbers (e.g., Haemophilus-like organisms, §12 tion-free intervals varied [9 -15] . Notably, older first-and second-generation oral cephalosporins (e.g., cephalexin and morphologiccal types per oil immersion field; pneumococcuslike organisms, §8 morphological types per oil immersion cefaclor) were reported to be less-than-optimal treatment partly because of emerging resistance of the common bacterial pathofield; M. catarrhalis -like organisms, §18 morphological types per oil immersion field; or gram-negative bacilli, §2 morphogens causing ABECB [9, 16] .
Earlier investigations with ciprofloxacin as treatment of logical types per oil immersion field) with or without other laboratory evidence of infection (e.g., increased WBC count). AECB showed that the fluoroquinolones were efficacious, although most previous studies were either small or nonblinded
Patients not meeting these gram staining criteria were presumed not to have a bacterial infection. comparative or noncomparative trials or employed few objective measurements [15 -24] . Clarithromycin, a relatively new Patients with any of the following characteristics were excluded from the investigation: evidence of a severe respiratory macrolide antimicrobial, was also shown to be at least as effective as ampicillin for treatment of ABECB [25 -27] .
tract infection that mandated parenteral antimicrobial therapy or mechanical ventilatory support; evidence of a new bronchoThe purpose of this trial was to compare the length of the infection-free interval between an ABECB and the next exacerpulmonary infiltrate or lobar consolidation on a chest roentgenogram; recent diagnosis or unresolved lung or chest cavity bation following treatment with ciprofloxacin or clarithromycin. Rates of clinical, bacteriologic, and safety responses malignancy; AIDS; active pulmonary tuberculosis; cystic fibrosis; symptomatic bronchiectasis; need for concomitant antiwere also contrasted between the two study drug groups. Importantly, in this study, assessment of sputum neutrophil levels microbial agents with a similar spectrum of activity to either study drug; allergy to carboxyquinolones or macrolide derivaand gram staining were employed, which allow the efficacy of various antimicrobial therapies to be compared for the managetives; administration of terfenadine, astemizole, or loratadine during the study period; previous enrollment in this study; ment of ABECB [3] . pregnancy or nursing; or a baseline serum creatinine level of §3.0 mg/dL. The study protocol was approved by each instituPatients and Methods tional review board, and written informed consent was obtained from each patient before study enrollment.
Selection of Patients
Hospitalized or ambulatory males and females at least 18
Study Design, Antimicrobial Therapy, and Scheduled years of age for whom the primary diagnosis was AECB were Assessments enrolled in this trial conducted in the United States and the Netherlands. Eligible adults who had chronic bronchitis with This was a prospective, multicenter, randomized, doubleblind, comparative study. Both study drugs were encapsulated associated chronic bronchial asthma, chronic obstructive pulmonary disease (COPD), or both as defined by the American in gelatin capsules for blinding purposes. Ciprofloxacin (Cipro, Bayer Corporation, Pharmaceutical Division, West Haven, CT) Thoracic Society [28] and who had an acute exacerbation of bronchitis due to a bacterial pathogen were eligible for study and clarithromycin (Biaxin, Abbott Laboratories, Abbott Park, IL) were supplied as 250-mg tablets. All patients received two enrollment. At the pretherapy visit, a complete medical history and physical examination were performed with emphasis on capsules twice daily for 14 days. Patients were advised to take study medication with the morning and evening meals. respiratory signs and symptoms; in addition, standard hematologic and biochemical laboratory tests were performed, and a Concomitant antibacterial agents were not allowed during the study period. If necessary, use of bronchodilators, mucolytics, baseline chest roentgenogram was obtained.
Acute bronchial infectious exacerbations were defined by or expectorants was permitted during the study period. Antimicrobial effectiveness was evaluated by means of cliniclinical and laboratory criteria. Only patients with mild to moderately severe respiratory exacerbations were enrolled in the cal analyses (i.e., chest examination and assessment of respiratory symptoms) and laboratory measurements, including prestudy. These infections were clinically defined as follows: type 1, increased dyspnea, sputum volume, and sputum purulence; treatment and posttreatment sputum cultures and gram staining of sputum samples obtained 2, 12, 24, and 36 weeks after type 2, at least two of the three aforementioned symptoms; and type 3, at least one of the three previously described symptoms therapy or when a treatment failure or a new AECB occurred. Susceptibility of all isolated pathogens was determined by us- [6] . In addition, all patients had to present with at least one of ing the standard disk diffusion technique or by microdilution lessening of the signs and symptoms of infection such that additional or alternative antimicrobial therapy was required). procedures of the National Committee for Clinical Laboratory Standards [29, 30] . Patients from whom resistant organisms At the follow-up evaluations (at 2, 12, 24, and 36 weeks or at the time of the next acute exacerbation), the patient's clinical were isolated were not prematurely withdrawn from the study. Diagnostic tests were not used to evaluate the presence of viral, response was defined as either continued resolution or clinical relapse by using similar criteria. The response was considered mycoplasmal, or chlamydial organisms at any evaluation.
All patients who received the study drug comprised the inindeterminate if insufficient data were available or if the patient's response was confounded by other medical conditions tent-to-treat population. Safety of study drug treatment was monitored by clinical observations and, if clinically indicated, or concomitant medication. Bacteriologic response. Bacteriologic response was based by conventional laboratory tests of renal, hepatic, and hematologic function.
on the results of gram staining and the appropriate cultures of samples obtained before and after therapy. At the end of therTwo populations were evaluated in this study: the intent-totreat population and patients for whom efficacy of the study apy, bacteriologic response was graded as eradication, presumed eradication (i.e., no culture material from a patient for drug could be evaluated (the efficacy-valid population).
whom the clinical response was judged to be resolution), or persistence. In addition, superinfection was defined as clinical
Efficacy Evaluation
failure with a repeated sputum culture that identified a causative organism different from the pretherapy isolate and need for Criteria necessary for evaluation of efficacy included the following: acute respiratory tract infection confirmed by the alternative antimicrobial therapy. Bacteriologic responses at the follow-up evaluation included continued eradication, continued presence of signs and symptoms of infection; isolation and identification of a predominant pathogen within 48 hours of presumed eradication, relapse (reappearance of original causative organism), and reinfection (new causative organism idenreceiving the study drug; cultures of sputum obtained at designated posttherapy times; administration of the study drug for tified). Bacteriologic response was considered indeterminate if the pretherapy culture was negative, a culture specimen was at least 12 full days, unless treatment was a failure; and no other antimicrobial agent administered concomitantly with the not obtained from a patient whose clinical response was failure, or the response was confounded by concomitant antimicrobial study drug. Efficacy could not be evaluated for patients missing three consecutive days of study drug treatment. If therapy was therapy. Drug safety was evaluated for all patients who received at discontinued due to an adverse event, efficacy could not be evaluated for that patient unless treatment failed.
least one dose of the study drug (intent-to-treat population). Adverse events were ranked by the blinded investigator as The primary measure of study drug efficacy in this trial was the infection-free interval. Clinical failures during therapy were to their severity (mild, moderate, severe, or serious and lifethreatening) and by their relationship to the study antimicrobial counted as zero infection-free interval days. The infection-free interval for patients without a clinical relapse or new infection (probable, possible, remote, or none). during the 36-week posttherapy observation period was the number of days to the last time point for which information Statistical Analysis was known; therefore, the exact length of the infection-free interval at least equaled this reported value. Otherwise, the
The primary goal of this study was to compare the ciprofloxacin regimen with the clarithromycin regimen with renumber of days to the next clinical relapse or new infection was recorded.
spect to the infection-free interval between AECB. The secondary measures of efficacy were clinical and bacteriologic Clinical response. The parameters of clinical response, which was based on serial examinations of the patient by an responses at the end of therapy. With the size of the intent-totreat population enrolled, the study had a power of 90% to investigator blinded to treatment, were as follows: change in cough frequency and severity, sputum characteristics (purudetect a difference in time to relapse between the two study treatments on the basis of a survival analysis (two-sided lence and volume), auscultatory findings (rales, rhonchi, wheezing, and breath sounds), dyspnea, chest pain or discoma Å .05) [31] . Survival analysis techniques were employed for the infecfort, friction rub, prolongation of expiratory phase, fever (temperature, ú38ЊC), and WBC count of ú12,000/mm 3 . At the tion-free intervals. The Kaplan-Meier method was used to estimate the distributions of failure times. The estimated survival end of therapy, clinical response was defined as resolution (disappearance of acute signs and symptoms with complete function was plotted over time for each study drug group. The survival curves for each study drug were compared by using return to a stable preexacerbation condition of chronic bronchitis such that additional antimicrobial treatment was not necesa Wilcoxon rank test or a logrank test. For the end of therapy and follow-up evaluations and clinical sary), improvement (reduction in severity and/or number of signs and symptoms of infection with or without the need and bacteriologic responses, two-sided 95% confidence intervals were calculated for the differences between resolution or for additional antimicrobial therapy), or failure (insufficient eradication rates for ciprofloxacin and clarithromycin; a Cochof patients in both treatment groups received posttherapy systemic antimicrobials for either a relapse or a new AECB during ran-Mantel-Haenzel weighting procedure was used to adjust for the multicenter nature of the trial. The two treatments were the 36-week follow-up period. declared equivalent at the 2.5% significance level if the lower confidence limit was §00.10.
Treatment Efficacy
To test the comparability of the treatment groups, categorical variables including demographic and medical characteristics Clinical response. In the efficacy-valid population, clinical resolution at the end of therapy was reported for 90% of ciwere analyzed by using the Cochran-Mantel-Haenzel test (adjusting for the multicenter nature of the trial) or the x 2 test. profloxacin recipients and 82% of clarithromycin recipients (95% CI, 00.024 -0.174) ( figure 1 ). Of the 10 ciprofloxacin For continuous variables, an analysis of variance model was fitted with treatment group and treatment center as factors. The recipients for whom therapy failed, three had bacteriologic eradication, and six had documented persistence. Of the 16 incidence rates of adverse events were tabulated by treatment group and body system. clarithromycin recipients for whom therapy failed, nine had eradication or presumed eradication, and five had known persistence. Bacteriologic eradication at the end of therapy, including presumed eradication, revealed statistically significant differrecipients and 84 clarithromycin recipients) were excluded from the analysis of the efficacy-valid population. The primary ences between the study drugs (91% of ciprofloxacin recipients and 77% of clarithromycin recipients; 95% CI, 0.028 -reasons for exclusion included no pretherapy pathogen (113 patients) and an inadequate duration of treatment (28 patients).
0.242) ( figure 1 ). At the follow-up evaluation (time of clinical relapse or final follow-up visit), continued and/or presumed Reasons for premature discontinuation of study drug treatment were similar between the two treatment groups.
eradication was described in 64% of ciprofloxacin recipients and 58% of clarithromycin recipients in the efficacy-valid The baseline demographics and clinical characteristics of the intent-to-treat population were similar between the two population. There were no differences in the types of organisms causing relapse or reinfection between the two study treatment groups (table 1) . Approximately one-third of patients in each treatment group were active smokers. There was a drug groups. H. influenzae, M. catarrhalis, and S. pneumoniae were the most frequently isolated organisms causing restatistically significant difference between study drug groups regarding the general health status; 63% of ciprofloxacin recipilapse or reinfection. Of patients in the efficacy-valid population, six ciprofloxacin ents had excellent or good health reported compared with 53% of clarithromycin recipients (P Å .047). Most patients in each recipients had superinfections due to seven organisms (Staphylococcus aureus, 2; S. pneumoniae, 1; H. parainfluenzae, 1; treatment group had COPD and a type 1 AECB (table 1) . Sixtyeight percent to 70% of patients in both study drug groups had P. aeruginosa, 1; Stenotrophomonas maltophilia, 1; and Enterobacter agglomerans, 1). Of the clarithromycin recipients, two or less AECB during the past 12 months that required antimicrobial therapy, and Ç84% of these episodes were maneight had a superinfection (S. aureus, 2; H. influenzae, 1; H. parainfluenzae, 1; Haemophilus haemolyticus, 1; Escheaged in an outpatient setting.
Baseline demographic and clinical characteristics of the efrichia coli, 1; P. aeruginosa, 1; and Acinetobacter baumannii, 1). A total of 274 causative organisms (141 from ciprofloxacin ficacy-valid population were similar to those of the intent-totreat population. Clinical respiratory signs and symptoms that recipients and 133 from clarithromycin recipients) from 234 patients were isolated before initiation of study drug therapy. were present at study entry in the patients in the efficacy-valid population were comparable between both treatment groups.
Multiple causative organisms were isolated before therapy from 21 ciprofloxacin recipients and 17 clarithromycin recipients. In the efficacy-valid population, systemic antimicrobials were taken by 10 ciprofloxacin recipients (9%) and seven clarithro-
The (23) 59 (31) 21 (20) 25 (24) COPD 142 (77) 139 (74) 86 (80) 79 (76) Smoker 70 (38) 59 (31) 39 (36) 34 (33) Severity of infection Type 1 147 (80) 139 (74) 83 (78) 72 (69) Type 2 33 (18) 41 (22) 19 (18) 26 (25) Type 3 5 (3) 8 (4) 5 (5) (10) 11 (6) 15 (14) ‡ 6 (6) NOTE. Unless stated otherwise, data are no. (%) of patients with characteristic. COPD Å chronic obstructive pulmonary disease.
* Includes patients who were evaluable in terms of either bacteriologic or clinical findings; a pretherapy pathogen was not isolated from all patients.
† P Å .047; none of the remaining differences between the treatment groups were statistically significant for the intent-to-treat population.
‡ P Å .01; none of the remaining differences between the treatment groups were statistically significant for the efficacy-valid population.
P. aeruginosa, 1) from ciprofloxacin recipients and 24
one ciprofloxacin recipient from whom a resistant S. aureus isolate was recovered had a clinical failure and bacteriologic (H. influenzae, 15; P. aeruginosa, 3; H. parainfluenzae, 1; E. coli, 3; Proteus mirabilis, 1; and S. pneumoniae, 1) from persistence at the end of therapy. Four clarithromycin recipients from whom resistant organisms were isolated (Pseudomonas clarithromycin recipients were found to be persistent (table 2) . Of the six persistent pneumococcal pathogens from ciprofloxspecies, 3; and E. coli, 1) also had clinical failures. Few changes in patterns of antimicrobial resistance to either acin recipients, two were isolated from patients who had clinical resolutions, and four were isolated from patients with clinistudy drug were found for persistent or recurring pathogens. Pretherapy and follow-up susceptibility information was available cal failure. Four (27%) of 15 persistent H. influenzae pathogens from clarithromycin recipients were associated with clinical for 28 (10 persistent and 18 recurring) organisms from 25 ciprofloxacin recipients. For the 10 persistent pathogens, three failure.
Antimicrobial susceptibility patterns. There were 41 pathochanges in ciprofloxacin susceptibility patterns were reported: two S. pneumoniae isolates and one P. aeruginosa isolate went gens at the time of study entry that were resistant to either ciprofloxacin or clarithromycin, including one resistant to cifrom susceptible to intermediately resistant. For the 18 recurring pathogens, two changes in susceptibility patterns were found: profloxacin (S. pneumoniae), 39 resistant to clarithromycin (S. pneumoniae, 1; Pseudomonas species, 13; Haemophilus one S. pneumoniae isolate went from susceptible to both ciprofloxacin and clarithromycin to resistant, and one H. influenzae species, 9; Klebsiella species, 5; and miscellaneous gram-negative bacilli, 11); and one resistant to both study drugs isolate went from susceptible to clarithromycin to resistant. Pretherapy and follow-up susceptibility data were available for 42 (S. aureus). Nineteen of these 41 resistant organisms were isolated from patients in the efficacy-valid population (one (22 persistent and 20 recurring) organisms from 37 clarithromycin recipients. For the 22 persistent pathogens, three changes ciprofloxacin recipient and 18 clarithromycin recipients). The / 9c57$$oc06 09-23-98 14:48:06 cida UC: CID sea, dizziness (clarithromycin recipients only), dyspepsia (ciprofloxacin recipients only), and headache were the most common events reported ( §4%). Of the patients who experienced an adverse event, most had only mild or moderate adverse events (98% of ciprofloxacin recipients and 88% of clarithromycin recipients) that decreased or resolved. Study drug treatment was prematurely discontinued because of one or more adverse events in 14 ciprofloxacin recipients and 17 clarithromycin recipients. One ciprofloxacin recipient reported one severe adverse event that was possibly drug-related (vomiting), and six severe adverse events possibly related to clarithromycin (abdominal pain, bronchitis, rash, overdose, vertigo, and chest pain) were reported.
Discussion
This study confirmed the efficacy of ciprofloxacin, as observed by other investigators, in the treatment of ABECB. Importantly, this study enrolled patients who clearly had ABECB, on the basis of not only clinical presentation but also sputum examination revealing increased bacterial flora and neutrophils. Clinical resolution at the end of therapy with both ciprofloxacin and clarithromycin was similar. This finding is in agreewere found: three H. influenzae isolates went from susceptible to clarithromycin to resistant. For the 20 recurring pathogens, two changes were noted: two H. influenzae isolates went from (93) were found to influence the length of the infection-free period:
Haemophilus parainfluenzae 7/7 (100) 3/4 (75) the number of AECB episodes in the prior 12 months shorter infection-free interval in both study drug groups. When evaluating the efficacy-valid population, including patients with clinical failures at the end of therapy, ciprofloxacin was associated with a trend toward an infection-free interval longer than that associated with clarithromycin (142 days vs. 51 days, respectively; P Å .15). These findings suggest that many previously reported investigations of antimicrobial therapy for AECB have a serious design flaw. Many of these studies relied on evaluation of intent-to-treat populations for whom the bacterial etiologies of only a few exacerbations were tigation, the sensitivity of the comparison between the two antimicrobials was considerably enhanced when only bacterial exacerbations were analyzed. Although it is unlikely that emment with other clinical trials that evaluated ciprofloxacin [14 -24] or clarithromycin [25 -27] as treatment of ABECB. As pirical antimicrobial therapy for AECB cases can be discouraged, it is important to provide valid data concerning the effimight be expected for this population of patients with chronic bronchial disease, slightly greater than one-half of the patients cacy for ABECB since it is only in these cases that antimicrobial efficacy will be important. in both treatment groups were noted to clinically relapse during the 36-week follow-up period. Consequently, Ç50% of en-A retrospective exploratory analysis, including patients with clinical failures, was conducted after study completion to deterrolled patients required further systemic antimicrobial agents during the posttherapy follow-up period. However, some of mine if there were any differences in the infection-free interval on the basis of variances in age, sex, smoking status, general the AECB relapses may not have been solely related to bacterial infection since viral infection, allergy, problems of secretion health status, occurrence of an exacerbation in the prior year, severity of infection, presence of a pretherapy pathogen, and clearance, and therapy lapses (which are common in this patient population) may have been responsible. Nonetheless, quick presence of a persistent pathogen at the end of the study. Two variables were found to influence the length of the infectioninitiation of appropriate antimicrobial therapy should follow the suspicion of a bacterial infection such that unnecessary free period. Both a greater number of AECB episodes in the prior 12 months and the presence of a persistent pathogen at morbidity can be minimized.
This study demonstrated that the bacteriologic eradication study completion were associated with a shorter infection-free interval in both study drug groups (P õ .01). For the other rate associated with ciprofloxacin was statistically significantly higher than that associated with clarithromycin. A relatively exploratory variables, including treatment (P Å .67), there was not enough evidence to conclude that they had a statistically high rate of persistence with H. influenzae and miscellaneous gram-negative organisms was observed among clarithromycin significant effect on the infection-free interval. Although the present study demonstrated that the infectionpatients, in contrast to complete eradication following ciprofloxacin treatment. Of note, nine (9%) of 98 Haemophilus free interval following ciprofloxacin therapy was relatively long, the time to relapse may be dose-related. In the current isolates were resistant to clarithromycin at baseline, and five persistent or recurring pathogens developed resistance during study and in another recent trial of ciprofloxacin therapy for AECB, daily doses of 1,000 mg were associated with a similar the study period. Although S. pneumoniae was not uniformly eradicated by ciprofloxacin in this trial, a parallel study of median infection-free interval (146 days) [32] . However, a previously reported study that used a higher ciprofloxacin dosage ABECB found that 90% (nine of 10) of these isolates were eradicated at the end of therapy [32] . In addition, although the (750 mg twice daily) demonstrated a mean infection-free interval of 213 days [14] . Consequently, the 500-mg dose of ciin vitro activity of ciprofloxacin against gram-positive organisms (e.g., pneumococci) has been questioned [33, 34] , other profloxacin twice daily that was used in our study may, in part, be responsible for the shorter infection-free interval. However, studies on lower respiratory tract infections have demonstrated that ciprofloxacin is efficacious against most clinical gramoverall differences in the infection-free interval may also be related to varying styles of patient management. For example, positive isolates that are recovered [35 -38] . One (3%) of 39 S. pneumoniae isolates was resistant to ciprofloxacin at basethe study in which high doses of ciprofloxacin were used was / 9c57$$oc06 09-23-98 14:48:06 cida UC: CID
